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Volume 59, Number 6S Abstracts 91Sarm, n ¼ 242) or for endoleak/migration developing
remote from an initial endovascular repair (revision arm,
n ¼ 77). The primary arm was subdivided into (1) prophy-
lactic EA use for hostile neck anatomy, (2) use for acute
type Ia endoleak after endograft deployment, and (3) use
after unsatisfactory distal endograft deployment. The revi-
sion arm was subdivided into those undergoing treatment
for (1) type Ia endoleak alone, (2) migration alone, and
(3) migration with endoleak. Procedural success was
deﬁned as successful EA implantation without type Ia
endoleak on completion angiography, and clinical success
was deﬁned as procedural success without type Ia endoleak,
migration, >5 mm sac enlargement, or secondary proce-
dures over follow-up.
Results: Outcome after EA use was satisfactory over
early follow-up averaging 9 6 3 months, with absence of
type Ia endoleaks in 290 patients (90.9%), procedural suc-
cess in 279 patients (87.5%), and clinical success in 265 pa-
tients (83.1%) (Table).
Conclusions: EAs appear to offer a useful adjunct to
EVAR for prophylaxis against aortic neck complications
when hostile anatomy is encountered, and therapeutically
when aortic neck complications develop. Deﬁnitive conclu-
sions await the availability of longer-term follow-up data.Table. Imaging and clinical outcome by indication for
EndoAnchor use
Indications for
EndoAnchor use No.
Type Ia endoleak
at completion
Procedural
success
Clinical
success
No. (%) No. (%) No. (%)
Primary arm 242 19 (7.9) 217 (89.7) 208 (86.0)
Prophylactic 186 9 (4.8) 172 (92.5) 165 (88.7)
Acute endoleak 52 9 (17.3) 43 (82.7) 41 (78.8)
Distal deployment 4 1 (25.0) 2 (50.0) 2 (50.0)
Revision arm 77 10 (13.0) 62 (87.5) 57 (74.0)
Existing endoleak 45 9 (20.0) 35 (77.8) 32 (71.1)
Existing Migration 11 0 8 (72.2) 8 (72.7)
Endoleak and
migration
21 1 (4.8) 19 (90.5) 17 (81.0)Author Disclosures: J. de Vries: Aptus Endosystems,
research grants and Honorarium;W. Jordan: Aptus Endo-
systems, research grants and consulting fees or other remu-
neration (payment); M. Mehta: Aptus Endosystems,
research grants; K. Ouriel: Syntactx, employment (full or
part-time), and ownership or partnership, and Aptus Endo-
systems, consulting fees or other remuneration (payment).Table. ROC analyses of risk prediction models for disease prog
Risk of disease progression
Unadjusted HR (95% CI) Adjusted HR* (95%
PSV 1.01 (1.01-1.02) 1.01 (1.01-1.02
EDV 1.02 (1.01-1.03) 1.03 (1.01-1.04
ICA/CCA ratio 3.90 (2.19-5.25) 3.42 (2.16-5.41
PSV + ICA/CCA 2.60 (1.59-4.25) 2.63 (1.54-4.47
AUC, Area under the curve; CI, conﬁdence interval; HR, hazard ratio.
*Adjusted for age, smoking, and dual antiplatelet therapy.
**Model equation: Y ¼ exp(e4.84 + 0.005PSV e 0.97ratio e0.007Age + 0.56RR3.
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Objectives: Previously, we described risk factors for
disease progression in moderate asymptomatic carotid ar-
tery stenosis (ASCS). The aim of the current study was
to develop a risk prediction model for disease progression
in this group.
Methods: All patients presenting with moderate
(50%-69%) ASCS as determined by carotid artery duplex
(January 2005-May 2012) were included. Cox propor-
tional hazard regression models accounting for measured
duplex velocities (peak systolic velocity [PSV]; end-dia-
stolic velocity [EDV]; internal carotid artery [ICA]/
common carotid artery [CCA] ratio) and previously
identiﬁed risk factors for progression (age, smoking,
dual antiplatelet therapy) were used to develop receiver
operating characteristic (ROC) curves for predicting dis-
ease progression.
Results: A total of 268 patients (52% male) were
analyzed (71 6 9 years, 2.6 6 1.7 years followup, 25% dis-
ease progression). Initial PSV, EDV, and ICA/CCA ratio
were all signiﬁcant predictors of progression (Table).
ROC curve analyses suggested that a prediction model
including PSV, ICA/CCA ratio, age, smoking, and dual
antiplatelet therapy had optimal prediction efﬁcacy (C-sta-
tistic, 0.76; Table).
Conclusions: We propose a ﬁve-variable risk predic-
tion model that can be used to predict disease progression
in patients with moderate ASCS with good sensitivity and
speciﬁcity that may be useful for identifying high-risk pa-
tients requiring closer follow-up.
AuthorDisclosures: C. J. Abularrage: Nothing to disclose;
I. Arhuidese: Nothing to disclose; J. K. Canner: Nothing to
disclose; J. A. Freischlag: Nothing to disclose;C.W.Hicks:
Nothing to disclose; M. B. Malas: Nothing to disclose; B.
Perler: Nothing to disclose; U. Qazi: Nothing to disclose;
E. Schneider: Nothing to disclose; K. Talbott: Nothing to
disclose.ression in moderate asymptomatic carotid artery stenosis
C-statistic
CI) Unadjusted AUC (95% CI) Adjusted AUC* (95% CI)
) 0.68 (0.61-0.76) 0.71 (0.63-0.79)
) 0.64 (0.56-0.72) 0.68 (0.60-0.76)
) 0.74 (0.68-0.81) 0.75 (0.68-0.76)
) 0.75 (0.68-0.82) 0.76 (0.69-0.83)
Smoking + 0.40Antiplatelet).
